Tenax Therapeutics (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases, announced a major clinical milestone in its Phase 3 LEVEL trial.
Legend Biotech (NASDAQ:LEGN) reported a transformative fourth quarter and full year for 2025, headlined by the commercial success of its lead CAR-T therapy, CARVYKTI®.
SS Innovations International (NASDAQ:SSII), the developer of the SSi Mantra™—the first surgical robotic system to be commercially available in India—reported explosive growth for the fiscal year ended December 31, 2025.
Edgewise Therapeutics (NASDAQ:EWTX), a clinical-stage biopharmaceutical company developing orally bioavailable small molecules for rare muscle disorders, announced positive long-term results from its MESA open-label extension study of sevasemten.
ADC Therapeutics (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation antibody-drug conjugates (ADCs), reported a steady fourth quarter for 2025 and a significantly strengthened balance sheet on Tuesday.
BioNTech (NASDAQ:BNTX), the biotechnology firm that rose to global prominence with its COVID-19 vaccine, reported full-year 2025 revenues of €2.87 billion on Tuesday.
Apyx Medical (NASDAQ:APYX), an advanced energy technology company proprietary to the Renuvion® helium plasma platform, reported a net loss of $1.3 million for its fourth quarter on Tuesday.
Lipocine (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing oral delivery solutions for endocrine and metabolic disorders, reported a net loss of $2.4 million for the fourth quarter on Tuesday.
Q32 Bio (NASDAQ:QTTB), a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, provided a fourth-quarter 2025 corporate update that highlights a significantly strengthened balance sheet and clinical progress.
Medtronic (NYSE:MDT) announced a definitive agreement on Tuesday to acquire Scientia Vascular, a privately held medical technology firm specializing in high-performance access products for neurovascular procedures.
Esperion Therapeutics (NASDAQ:ESPR), the pharmaceutical company focused on lipid-management therapies, reported total revenue of $168.4 million for the fourth quarter, representing a 144% increase over the same period last year.
Spruce Biosciences (NASDAQ:SPRB) reported a significant reduction in annual operating expenses for 2025 on Monday, as the company successfully transitioned its clinical focus toward its enzyme replacement therapy for rare neurological disorders.
